We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+25.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$266M
AUM Growth
+$58.2M
(+28%)
Cap. Flow
+$10.2M
Cap. Flow
% of AUM
3.84%
Top 10 Holdings %
Top 10 Hldgs %
51.18%
Holding
88
New
23
Increased
18
Reduced
16
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$6.17M |
| 2 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$5.47M |
| 3 |
EVDY
Everyday Health, Inc.
EVDY
|
+$4.74M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$4.54M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RRM
RR MEDIA LTD ORD SHS (ISR)
RRM
|
+$8M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$3.32M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$3.2M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$3.02M |
| 5 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$2.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.34% |
| 2 | Technology | 2.54% |
| 3 | Industrials | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Rigel Pharmaceuticals
RIGL
$693M
| – | – |
-74,775
| Closed | -$2.14M |
|
77
Travere Therapeutics
TVTX
$5.11B
| – | – |
-98,788
| Closed | -$1.76M |
|
|
AGN
78
DELISTED
Allergan plc
AGN
| – | – |
-8,500
| Closed | -$1.96M |
|
|
RXDX
79
DELISTED
Ignyta, Inc.
RXDX
| – | – |
-229,748
| Closed | -$1.25M |
|
|
CYNA
80
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| – | – |
-115,400
| Closed | -$1.93M |
|
|
RLYP
81
CALL
DELISTED
RELYPSA INC COM
RLYP
| – | – |
-10,000
| Closed | -$185K |
|
|
RRM
82
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
| – | – |
-611,818
| Closed | -$8M |
|
|
BEAT
83
DELISTED
BioTelemetry, Inc.
BEAT
| – | – |
-34,630
| Closed | -$564K |
|
|
CYTR
84
PUT
DELISTED
CytRx Corp
CYTR
| – | – |
-16,667
| Closed | -$223K |
|
|
SGY
85
PUT
DELISTED
Stone Energy
SGY
| – | – |
-19,026
| Closed | -$1.3M |
|
|
RPTP
86
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| – | – |
-174,708
| Closed | -$938K |
|
|
MDVN
87
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-50,000
| Closed | -$3.02M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q3 2016 Portfolio in Review
As of Q3 2016, Acuta Capital Partners held 88 positions worth $266M, up 28% from $208M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Acuta Capital Partners deployed $10.2M of net new capital in Q3 2016, opening 23 new positions and adding to 18 existing holdings. Its largest new stake was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 73% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Amicus Therapeutics, an estimated $3.32M trimmed.
- Acuta Capital Partners's largest Q3 2016 buy was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.
- Acuta Capital Partners added most to Chembio diagnostics, Inc. in Q3 2016, an estimated $5.47M increase.
- Acuta Capital Partners's biggest Q3 2016 reduction was Amicus Therapeutics, cutting an estimated $3.32M.
- Acuta Capital Partners fully exited RR MEDIA LTD ORD SHS (ISR) in Q3 2016, selling an estimated $8M.
- Acuta Capital Partners's ten largest holdings make up 51% of its $266M portfolio in Q3 2016.
- Acuta Capital Partners opened 23 new positions and closed 21 in Q3 2016.
- Acuta Capital Partners's portfolio value rose 28% quarter-over-quarter to $266M.
Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.